Development of Predictive in vitro Methods for Characterizing Product Performance, using , Case Study: Furosemide

Information

  • Research Project
  • 8892292
  • ApplicationId
    8892292
  • Core Project Number
    U01FD005307
  • Full Project Number
    1U01FD005307-01
  • Serial Number
    005307
  • FOA Number
    RFA-FD-14-080
  • Sub Project Id
  • Project Start Date
    9/10/2014 - 10 years ago
  • Project End Date
    8/31/2016 - 8 years ago
  • Program Officer Name
  • Budget Start Date
    9/10/2014 - 10 years ago
  • Budget End Date
    8/31/2015 - 9 years ago
  • Fiscal Year
    2014
  • Support Year
    01
  • Suffix
  • Award Notice Date
    9/10/2014 - 10 years ago

Development of Predictive in vitro Methods for Characterizing Product Performance, using , Case Study: Furosemide

RFA-FD-14-080: Predictive in vitro Methods for Characterizing Product Performance, Case Study: Furosemide Project Summary / Abstract: The overall aim of the current grant application is to develop in vitro models that can predict drug performance in the pediatric patient. This will be achieved in an iterative process. First a throughout review of the gastro-intestinal physiology of the pediatric patient will be carried out. Then, based on this, a range of physiologically relevant media, simulating the pediatric gastric and intestinal fluids, will be composed. These will also include typically infant meals, such as milk, baby formula and Ensure Plus. The media will be used in modified compendial dissolution apparatuses, adjusted eg with regard to volume, to better simulate the pediatric patient. In addition, models closer simulating the gastro- intestinal physiology, eg the Dynamic Gastric Model will be employed. Data obtained will be compared to available in vivo data, and the models modified as to optimize the prediction of the in vivo performance. Finally, the data will be used in the development of physiologically based pharmacokinetic models. The project will therefore increase the current knowledge and understanding of the performance of poorly soluble drugs in the pediatric population and as such provide a basis for better formulations and thereby also an improved dosing regime for the better of the pediatric patient.

IC Name
FOOD AND DRUG ADMINISTRATION
  • Activity
    U01
  • Administering IC
    FD
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    99895
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
  • Ed Inst. Type
  • Funding ICs
    FDA:99895\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ZFD1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    UNIVERSITY OF COPENHAGEN
  • Organization Department
  • Organization DUNS
    310861591
  • Organization City
    COPENHAGEN
  • Organization State
  • Organization Country
    DENMARK
  • Organization Zip Code
    1017
  • Organization District
    DENMARK